

Fax: +49 941 944-4233 or
 Online registration:
 www.congress-registration.ukr.de

GvH/GvL 2018 - 14th International Symposium

Venue and Date

March 7 to 9, 2018
 Salzstadel Regensburg
(GHV-1803)

Yes, I am participating

- three days (March 7 to 9, 2018)**
- dinner (March 8, 2018)**

Your registration is binding. In case of a cancellation the cancellation statement must be in writing.

Title

First name

Last name

Hospital

Department

Adress

.....

Phone

Mail

.....

Date Signature

Main Sponsors

Neovii Biotech GmbH	25000 €
AMGEN GmbH	12000 €

Sponsors

Alexion Pharma Germany GmbH	1000 €
Biotest AG	2500 €
Bristol-Myers Squibb	3000 €
Celgene GmbH	1000 €
Chugai Pharma	1200 €
Gilead Sciences GmbH	1000 €
HEXAL AG	1250 €
Janssen Cilag	2500 €
Jazz Pharma	2500 €
Maco Pharma International GmbH	2500 €
Mallinckrodt Pharmaceuticals	2500 €
Medac GmbH	4000 €
Miltenyi Biotec GmbH	2500 €
MSD GmbH	3000 €
Novartis Pharma GmbH	2500 €
Pfizer Pharma GmbH	1500 €
Riemser AG	2000 €
Roche Pharma AG	1000 €
Shire	750 €
Takeda Pharma Vertrieb GmbH & Co. KG	750 €

Venue

Salzstadel Regensburg
 Weiße-Lamm-Gasse 1
 93047 Regensburg

Organisation

Britta Haseneder
 University Hospital Regensburg
 Phone: +49 941 944-4230,
 Fax: +49 941 944-4233, kongresse@ukr.de

Information

Susanna Piltauer
 Department of Internal Medicine III
 University Hospital Regensburg,
 Phone: +49 941 944-5542, Fax: +49 941 944-5543,
 susanna.piltauer@ukr.de

Participation Fee


Early bird until January 14, 2018	80 €
Regular fee after January 14, 2018	110 €
Conference diner (in addition)	40 €

Condition for Participation & Cancellation

After your successful registration you will receive an invoice concerning your participation fee during the next days by email. Once registered your registration is binding. All payments must be made prior to the conference. Participation fees are due upon receipt of invoice without deduction. Please transfer the invoice amount before the event date. In case of a cancellation the cancellation statement must be in writing. The following processing fees apply: 8-3 working days before the event 50% of participation fee. In case of too late cancellation or absence without written cancellation the entire fee will be charged. A substitute participant may be submitted at any time.

Your participation at this event is also an agreement that any film or photo material taken during the event may be publicly used on behalf of the UKR.

GRAFT VERSUS HOST
G>H
G>L
 GRAFT VERSUS LEUKEMIA



Graft versus Host Competence Center
 Department of Internal Medicine III

GvH/GvL 2018
 14th International Symposium

Salzstadel Regensburg, Germany

March 7 to 9, 2018

Dear colleagues,

It is our great honour and pleasure to welcome you for the 14. GvH/GvL meeting in our historical city of Regensburg. Since the first GvH/GvL meeting held in Munich the idea of a focussed and interactive meeting allowing extensive exchange and discussion among experts and young interested colleagues and on site development of concepts and ideas seems to meet the needs and the interest of many colleagues involved in the field of allogeneic stem cell transplantation and clinical immunobiology, especially in times of exciting new developments like the clinical introduction of CAR-T cells or the integration of the microbiome in pathophysiological concepts. Therefore, we are more than grateful that so many distinguished experts from all over the world have again accepted our invitation to contribute as speakers, chairs and discussants to a creative and stimulating 2018 meeting.

We hope that you enjoy our meeting and your visit in Regensburg!

Local Scientific Committee

Matthias Edinger
Herman Einsele
Wolfgang Herr
Petra Hoffmann
Ernst Holler
Hans Jochem Kolb
Marina Kreutz
Andreas Mackensen
Daniel Wolff

Wednesday, March 7th, 2018

1.00 pm **Welcome**

Session I: Acute GvHD – Pathophysiology and Biomarkers

Chairs: J. Finke, H. J. Kolb

1.15 pm **DAMPs and innate immune cells**

R. Zeiser, Freiburg

1.40 pm **RIGI/MAVS signalling**

H. Poeck, München

2.05 pm **Angiogenesis**

O. Penack, Berlin

2.30 pm **Biomarker scores, are we ready to use them?**

J. Levine, New York

2.55 pm **Biomarkers and pathophysiology**

J. L. M. Ferrara, New York

3.20 pm [Coffee Break](#)

Session II: New worlds: The Microbiome and Virome

Chairs: A. Beilhack, A. Gerbitz

4.00 pm **Microbiota and intestinal inflammation in IBD**

D. Haller, München/Freising-Weißenstephan

4.25 pm **Loss of Diversity and Outcome**

R. Jenq, Houston

4.50 pm **New aspects of the interaction of antibiotics and inflammation**

E. Holler, Regensburg

5.15 pm **First experiences on FMT in allogeneic SCT recipients**

P. Neumeister, Graz

5.40 pm [Keynote lecture](#)

Next omics: Virome and beyond in allogeneic SCT

G. Socie, Paris

6.30 pm [Evening Discussion with beer and brezels](#)

What's next in GvHD: Biomarker triggered early treatment or preemption or better and different drugs for steroid resistant GvHD?

Thursday, March 8th, 2018

Session I: Immunoregulation and new issues

Chairs: H. Einsele, P. Hoffmann

8.30 am **Vedulizomab in GI GvHD**

Y. Floisand, Oslo

8.55 am **New issues in steroid resistant acute GvHD**

G. Socie, Paris

9.20 am **Vit D – new aspects**

M. Kreutz, Regensburg

Session II: Car T cell and beyond, part 1

Chairs: M. Hudecek, A. Mackensen

10.00 am **Donor CD19 CAR-T cells – GvL without GvHD?**

M. v. d. Brink, New York

10.25 am **B cell specific CAR-modified memory stem cells**

L. Gattinoni, Maryland

10.50 am **Using T-cells and the T-cell receptor for Cancer Immunotherapy**

A. Sewell, Cardiff

11.05 am [Coffee Break](#)

Session III: Chronic GvHD

Chairs: I. Na, D. Wolff

11.30 am **Biomarkers of cGvHD**

H. Greinix, Graz

11.55 am **IgG Glycosylation and autoimmune disorders**

M. Ehlers, Lübeck

12.20 pm **Follicular Helper Cells**

E. Forcade, Bordeaux

12:45 pm **First line treatment of cGvHD with Rituximab**

F. Malard, Paris

1.10 pm [Lunch](#)

Session IV: GvL – checkpoint inhibitors and immune escape

Chairs: P. Beckhove, S. Thomas

2.00 pm **Ipilimumab and leukemia relapse**

R. Soiffer, Boston

2.25 pm **Neoantigen heterogeneity and sensitivity to checkpoint inhibition**

K. Peggs, London

2.50 pm **Nivolumab and allogeneic SCT**

C. Herbaux, Lille

3.15 pm **PD1 and the tumor niche**

P. Bousso, Paris

3.40 pm **ROS in GvL**

D. Mougiakakos, Erlangen

4.00 am [Coffee Break](#)

4.30 pm [HJ Kolb Award and Award lecture](#)

[Dinner at Spitalgarten, Regensburg](#)

Friday, March 9th, 2018

Session I: CAR T cells, part 2

Chairs: P. Bader, W. Herr

8.30 am **New Targets and Technologies for CAR-T**

M. Hudecek, Würzburg

8.55 am **CD30 CAR**

H. Abken, Köln

9.20 am **CD38 CAR-T cells**

T. Mutis, Amsterdam

9.45 am **Steering of CARs**

M. Bachmann, Dresden

10.10 am [Coffee Break](#)

Session II: Cellular therapy: Regulatory T-cells and MSC

Chairs: H. Einsele, P. Hoffmann

10.30 am **Tissue specific T regs**

M. Feuerer, Regensburg

10.55 am **Update on T regs in HSCT**

M. Edinger, Regensburg

11.20 am **A novel mesenchymal stroma cell product (MSC-FFM) for the treatment of steroid and treatment-refractory aGvHD**

P. Bader, Frankfurt

11.45 am [Lunch](#)

Session III: GvL - Antigens and more

Chairs: K. Fleischhauer, A. Kremer

12.15 pm **Targeting of cancer neoantigens with donor derived T cell receptors**

J. Olweus, Oslo

12.40 pm **Organ specific HLA DP expression**

F. Falkenburg, Leiden

1.05 pm **Targeting of leukemic progenitor cells by cytotoxic T cells**

J. Greiner, Stuttgart

1.30 pm **MRD in AML and outcome**

E. Rego, Sao Paulo

1.55 pm **Microbiota and relapse following allogeneic SCT**

T. Peled, New York

2.20 pm [Summary and closure of the meeting](#)